The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice | springermedizin.de

Springer Medizin

nach oben

Cardiovascular Drugs and Therapy

Erschienen in:

01.10.2012

The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice

Dabigatran etexilate and atherosclerosis

verfasst von: Nikolaos P. E. Kadoglou, Petros Moustardas, Michael Katsimpoulas, Alkistis Kapelouzou, Nikolaos Kostomitsopoulos, Katrin Schafer, Alkiviadis Kostakis, Christos D. Liapis

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dabigatran etexilate (DE) constitutes a novel, direct thrombin inhibitor. Regarding the association of thrombin with atherogenesis, we assessed the effects of DE on the development and stability of atherosclerotic lesions in apolipoprotein-E deficient (ApoE−/−) mice.

Materials-methods

Fifty male ApoE−/− mice were randomized to receive western-type diet either supplemented with DE 7.5 mg DE/g chow) (DE-group, n = 25) or matching placebo as control (CO-group, n = 25) for 12 weeks. After this period, all mice underwent carotid artery injury with ferric chloride and the time to thrombotic total occlusion (TTO) was measured. Then, mice were euthanatized and each aortic arch was analyzed for the mean plaque area, the content of macrophages, elastin, collagen, nuclear factor kappaB (NFκB), vascular cell adhesion molecule-1 (VCAM-1), matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1).

Results

DE-group showed significantly longer TTO compared to CO-group (8.9 ± 2.3 min vs 3.5 ± 1.1 min, p < 0.001) and the mean plaque area was smaller in DE-group than CO-group (441.00 ± 160.01 × 10³ μm² vs 132.12 ± 32.17 × 10³ μm², p < 0.001). Atherosclerotic lesions derived from DE-treated mice showed increased collagen (p = 0.043) and elastin (p = 0.031) content, thicker fibrous caps (p < 0.001) and reduced number of internal elastic lamina ruptures per mm of arterial girth (p < 0.001) when compared to CO-group. Notably, DE treatment seemed to promote plaque stability possibly by reducing concentrations of NFκB, VCAM-1, macrophages and MMP-9 and increasing TIMP-1 within atherosclerotic lesions (p < 0.05).

Conclusions

DE attenuates arterial thrombosis, reduces lesion size and may promote plaque stability in ApoE−/− mice. The plaque-stabilizing effects of chronic thrombin inhibition might be the result of the favorable modification of inflammatory mechanisms.

Anzeige

1.

Ambrose JA, Srikanth S. Vulnerable plaques and patients: improving prediction of future coronary events. Am J Med. 2010;123:10–6.PubMedCrossRef

2.

Kadoglou NP, Kostomitsopoulos N, Kapelouzou A, Moustardas P, Katsimpoulas M, Giagini A, et al. Effects of exercise training on the severity and composition of atherosclerotic plaque in apoE-deficient mice. J Vasc Res. 2011;48:347–56.PubMedCrossRef

3.

Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009;102:248–57.PubMed

4.

Hamilton JR, Cocks TM. Heterogeneous mechanisms of endothelium-dependent relaxation for thrombin and peptide activators of protease-activated receptor-1 in porcine isolated coronary artery. Br J Pharmacol. 2000;130:181–8.PubMedCrossRef

5.

Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27:27–36.PubMedCrossRef

6.

Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet colloquium participants. Platelet functions beyond hemostasis. J Thromb Haemost. 2009;7:1759–66.PubMedCrossRef

7.

Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15:254–9.PubMedCrossRef

8.

Tracy R. Thrombin, inflammation, and cardiovascular disease. Chest. 2003;124:49S–57.PubMedCrossRef

9.

Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–62.PubMed

10.

Harenberg J, Marx S, Wehling M, Krejczy M. New anticoagulants - promising and failed developments. Br J Pharmacol. 2012;165:363–72.PubMedCrossRef

11.

Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436–50.PubMedCrossRef

12.

Fuster JJ, Castillo AI, Zaragoza C, Ibáñez B, Andrés V. Animal models of atherosclerosis. Prog Mol Biol Transl Sci. 2012;105:1–23.PubMedCrossRef

13.

Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood. 2007;110:4261–7.PubMedCrossRef

14.

Rotzius P, Thams S, Soehnlein O, Kenne E, Tseng CN, Bjorkstrom NK, et al. Distinct infiltration of neutrophils in lesion shoulders in apoe−/−mice. Am J Pathol. 2010;177:493–500.PubMedCrossRef

15.

Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin. 2004;20:419–32.PubMedCrossRef

16.

Pynn M, Schäfer K, Konstantinides S, Halle M. Exercise training reduces neointimal growth and stabilizes vascular lesions developing after injury in apolipoprotein e-deficient mice. Circulation. 2004;109:386–92.PubMedCrossRef

17.

Tracqui P, Broisat A, Toczek J, Mesnier N, Ohayon J, Riou L. Mapping elasticity moduli of atherosclerotic plaque in situ via atomic force microscopy. J Struct Biol. 2011;174:115–23.PubMedCrossRef

18.

Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2787–92.PubMedCrossRef

19.

Testa L, Bhindi R, Agostoni P, Abbate A, Zoccai GG, van Gaal WJ. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf. 2007;6:397–406.PubMedCrossRef

20.

Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology Working Group on atherosclerosis and vascular biology. Thromb Haemost. 2011;106:1–19.PubMedCrossRef

21.

Clarke M, Bennett M. The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol. 2006;26:531–5.PubMedCrossRef

22.

Olson ES, Whitney MA, Friedman B, Aguilera TA, Crisp JL, Baik FM, et al. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol (Camb). 2012;4:595–605.CrossRef

23.

Pou J, Rebollo A, Piera L, Merlos M, Roglans N, Laguna JC, et al. Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochim Biophys Acta. 2011;1813:1254–60.PubMedCrossRef

24.

DeGraba TJ. Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke. 2004;35:2712–9.PubMedCrossRef

25.

Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med. 2007;17:253–8.PubMedCrossRef

26.

Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther. 2007;7:855–70.PubMedCrossRef

27.

Kaur J, Woodman RC, Kubes P. P38 MAPK: critical molecule in thrombin-induced NF-kappa B-dependent leukocyte recruitment. Am J Physiol Heart Circ Physiol. 2003;284:H1095–103.PubMed

28.

Jennewein C, Paulus P, Zacharowski K. Linking inflammation and coagulation: novel drug targets to treat organ ischemia. Curr Opin Anaesthesiol. 2011;24:375–80.PubMedCrossRef

29.

Graebe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucosepositron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714–21.PubMedCrossRef

30.

de Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, van Berkel TJ, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:340–6.PubMedCrossRef

31.

Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005;56:173–89.PubMedCrossRef

32.

Holven KB, Halvorsen B, Bjerkeli V, Damås JK, Retterstøl K, Mørkrid L, et al. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects. Stroke. 2006;37:1731–6.PubMedCrossRef

33.

Skjøt-Arkil H, Barascuk N, Register T, Karsdal MA. Macrophagemediatedproteolytic remodeling of the extracellular matrix in atherosclerosis results inneoepitopes: a potential new class of biochemical markers. Assay Drug Dev Technol. 2010;8:542–52.PubMedCrossRef

Titel: The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice
Dabigatran etexilate and atherosclerosis
verfasst von: Nikolaos P. E. Kadoglou
Petros Moustardas
Michael Katsimpoulas
Alkistis Kapelouzou
Nikolaos Kostomitsopoulos
Katrin Schafer
Alkiviadis Kostakis
Christos D. Liapis
Publikationsdatum: 01.10.2012
Verlag: Springer US
Erschienen in: Cardiovascular Drugs and Therapy / Ausgabe 5/2012
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-012-6411-3

Anzeige

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen